Search results for: rare disease

Clinical trial design for HTA

Clinical evidence relating to therapeutic efficacy and safety is one of the most valuable criteria o...

Read more
Subscription style payment model

To tackle antibiotic resistance, novel antibiotics are being reserved as later-line therapy for more...

Read more
NRDL expansions

China has the second largest healthcare system in the world. However, this market has been challengi...

Read more
Improving access to innovative medicine in the UK

Following Brexit, the Medicines and Healthcare Regularoty Agency (MHRA) has become the UK's sole bod...

Read more
New PMPRB guidelines in Canada

The Patented Medicine Prices Review Board (PMPRB) has a mandate to ensure that patented medicines ar...

Read more
Pricing implications for cell and gene therapies

Cell and gene therapies - life saving opportunity for many patients

Read more
Revisiting the influence of ICER in the US

ICER’s Health Technology Assessments review process is an assessment undertaken by one of three ap...

Read more
Access to orphan drugs in the EU

Differences in market access and reimbursement processes are an important factor in determining the ...

Read more
Recommendations for market access reforms

This resolution includes proposed reforms to the market access (including pricing) landscape designe...

Read more
Greater access to medicines in the UK

NHS England is developing a new Commercial Framework, outlining potential opportunities for commerci...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch